Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 3/2018

01-06-2018 | Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation

Authors: Anjli Maroo, Johnny Chahine

Published in: Current Heart Failure Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

We describe contraception for two groups of women: (1) women with heart failure and (2) women with cardiac transplantation.

Recent Findings

Medical Eligibility Criteria for contraceptive agents address women with peripartum cardiomyopathy and women with valvular heart disease (Curtis et al. MMWR Recomm Rep 65:1–103, 2016). Recommendations for women with other forms of heart failure are extrapolated from these populations. Recommendations for women with cardiac transplantation have shifted since the 1980s: use of long-acting reversible contraception has increased, and there is a better understanding of the interactions between contraceptive and immunosuppressive regimens.

Summary

Women with heart failure may utilize long-acting reversible contraception and permanent sterilization. Modifications should be made according to the specific etiology of the heart failure. In women with cardiac transplantation, pregnancy is high risk and should be avoided altogether for 1–2 years after transplantation. In uncomplicated transplantation, almost all forms of contraception are allowable. In complicated transplantation, combined hormonal contraceptives are contraindicated, and de novo IUD insertion is not recommended.
Literature
1.
Estensen M, Gude E, Ekmehag B, Lommi J, Bjortuft O, Mortensen S, et al. Pregnancy in heart- and heart/lung recipients can be problematic. Scand Cardiovasc J. 2011;45:349–53.CrossRefPubMed
2.
Grewal J, Silversides CK, Colman JM. Pregnancy in women with heart disease: risk assessment and management of heart failure. Heart Fail Clin. 2014;10:117–29.CrossRefPubMed
3.
4.
Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009;95:680–6.CrossRefPubMed
5.
•• Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103. The Centers for Disease Control and Prevention Medical Eligibility Criteria (CDC-MEC) document provides guidelines for use of contraceptive agents in multiple different populations, including patients with cardiac risk factors, heart failure, and solid organ transplantation.
6.
• World Health Organization Medical Eligibility Criteria for Contraceptive Use, Fifth Edition. Geneva. 2015. WHO reference number: WHO/RHR/15.07. The World Health Organization Medical Eligibility Criteria document also provides guidelines for mutiple different populations.
7.
• World Health Organization Medical Eligibility Criteria for Contraceptive Use, Fourth Edition. Geneva. 2010. The World Health Organization Medical Eligibility Criteria document also provides guidelines for mutiple different populations.
8.
• Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR, Doria C, McGrory CH, Armenti VT. Report from the national transplantation pregnancy registry (ntpr): outcomes of pregnancy after transplantation. Clin Transpl. 2010;7:65–85. The NTPR collects outcome data on patients with solid organ transplant, including cardiac transplant, who undergo pregnancy.
9.
10.
Tran DD, Kobashigawa J. A review of the management of pregnancy after cardiac transplantation. Clin Transpl. 2015;31:151–61.PubMed
11.
Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care. 2008;34:237–46.CrossRefPubMed
12.
Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10:1–10.CrossRefPubMed
13.
14.
Erkkola R, Landgren BM. Role of progestins in contraception. Acta Obstet Gynecol Scand. 2005;84:207–16.CrossRefPubMed
15.
Giribela CR, Consolim-Colombo FM, Nisenbaum MG, Moraes TL, Giribela AH, Baracat EC, et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015;31:912–5.CrossRefPubMed
16.
Nisenbaum MG, de Melo NR, Giribela CR, de Morais TL, Guerra GM, de Angelis K, et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014;175:62–6.CrossRefPubMed
17.
Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet. 1997;59:237–43.CrossRefPubMed
18.
Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin N Am. 2011;40:419–32. ix CrossRef
19.
20.
Khalil RA. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol. 2013;86:1627–42.CrossRefPubMed
21.
22.
Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8–15.CrossRefPubMed
23.
Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.CrossRefPubMed
24.
25.
Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.CrossRefPubMedPubMedCentral
26.
27.
Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183:E1319–25.CrossRefPubMedPubMedCentral
28.
Sedlak T, Shufelt C, Iribarren C, Lyon LL, Bairey Merz CN. Oral contraceptive use and the ecg: evidence of an adverse qt effect on corrected qt interval. Ann Noninvasive Electrocardiol. 2013;18:389–98.CrossRefPubMedPubMedCentral
29.
Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex hormones and the qt interval: a review. J Women's Health (Larchmt). 2012;21:933–41.CrossRef
30.
Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ. Oral contraceptive use and the risk of cardiac events in patients with long qt syndrome. Heart Rhythm. 2014;11:1170–5.CrossRefPubMed
31.
Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95:130–9.CrossRefPubMed
32.
Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (chcs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87:93–100.CrossRefPubMed
33.
Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception. 2004;69:89–97.CrossRefPubMed
34.
Wang Q, Wurtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45:1445–57.CrossRefPubMedPubMedCentral
35.
36.
Dilshad H, Ismail R, Naveed S, Usmanghani K, Alam MT, Sarwar G. Effect of hormonal contraceptives on serum lipids: a prospective study. Pak J Pharm Sci. 2016;29:1379–82.PubMed
37.
Kongsayreepong R, Chutivongse S, George P, Joyce S, McCone JM, Garza-Flores J, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of dmpa and a control group of iud users. World Health Organization. Task force on long-acting systemic agents for fertility regulation special programme of research, development and research training in human reproduction. Contraception. 1993;47:177–91.CrossRefPubMed
38.
Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112:788–99.CrossRefPubMedPubMedCentral
39.
Villas-Boas J, Vilodre LC, Malerba H, Pontremoli Salcedo M, Foresti Jimenez M, El Beitune P. Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period. Eur J Obstet Gynecol Reprod Biol. 2016;202:51–4.CrossRefPubMed
40.
Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in adolescents: evaluation of clinical aspects. Contraception. 2011;83:336–9.CrossRefPubMed
41.
Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ. Influence of oral progesterone administration on drug-induced qt interval lengthening: a randomized, double-blind, placebo-controlled crossover study. JACC Clin Electrophysiol. 2016;2:765–74.CrossRefPubMedPubMedCentral
42.
Zigler RE, McNicholas C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol. 2017;216:443–50.CrossRefPubMed
43.
Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212:50 e51–8.CrossRef
44.
Moss C, Isley MM. Sterilization: a review and update. Obstet Gynecol Clin N Am. 2015;42:713–24.CrossRef
45.
Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375:555–62.CrossRefPubMed
46.
Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2017;8:CD001324.PubMed
47.
Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015;36:1728–34. 1734a-1734b CrossRefPubMed
48.
Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15–21.CrossRefPubMed
49.
Scala C, Leone Roberti Maggiore U, Remorgida V, Venturini PL, Ferrero S. Drug safety evaluation of desogestrel. Expert Opin Drug Saf. 2013;12:433–44.CrossRefPubMed
50.
Bianca I, Geraci G, Gulizia MM, Egidy Assenza G, Barone C, Campisi M, et al. Consensus document of the Italian Association of Hospital Cardiologists (anmco), Italian Society of Pediatric Cardiology (sicp), and Italian Society of Gynaecologists and Obstetrics (sigo): pregnancy and congenital heart diseases. Eur Heart J Suppl. 2017;19:D256–92.CrossRefPubMedPubMedCentral
51.
Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation. 2007;116:1736–54.CrossRefPubMed
52.
Yu AF, Steingart RM, Fuster V. Cardiomyopathy associated with cancer therapy. J Card Fail. 2014;20:841–52.CrossRefPubMed
53.
Casey PM, Faubion SS, MacLaughlin KL, Long ME, Pruthi S. Caring for the breast cancer survivor's health and well-being. World J Clin Oncol. 2014;5:693–704.CrossRefPubMedPubMedCentral
54.
Bordignon S, Aramayo AM, Nunes e Silva D, Grundler C, Nesralla I. Pregnancy after cardiac transplantation. Report of one case and review. Arq Bras Cardiol. 2000;75:515–22.CrossRefPubMed
55.
McKay DB, Josephson MA, Armenti VT, August P, Coscia LA, Davis CL, et al. Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant. 2005;5:1592–9.CrossRefPubMed
56.
• Cimino FM, Snyder KA. Primary care of the solid organ transplant recipient. Am Fam Physician. 2016;93:203–10. Review of common medical issues affecting patients with solid organ transplant. PubMed
57.
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.CrossRefPubMed
58.
Krajewski CM, Geetha D, Gomez-Lobo V. Contraceptive options for women with a history of solid-organ transplantation. Transplantation. 2013;95:1183–6.CrossRefPubMed
59.
• Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116–25. Review of management of pregnancy in patients with solid organ transplantation, including discussion of appropriate contraception counseling. PubMedPubMedCentral
60.
61.
Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16(Suppl 1):121–4.CrossRefPubMed
62.
Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990;323:693–9.CrossRefPubMed
63.
Bennett AL, Ventura HO. Hypertension in patients with cardiac transplantation. Med Clin North Am. 2017;101:53–64.CrossRefPubMed
64.
65.
Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008;3 Suppl 2:S38–48.CrossRefPubMed
66.
Huguelet PS, Sheehan C, Spitzer RF, Scott S. Use of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients: a case series. Contraception. 2017;95:378–81.CrossRefPubMed
67.
Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception. 2012;86:288–9.CrossRefPubMed
68.
Kossoy LR, Herbert CM 3rd, Wentz AC. Management of heart transplant recipients: guidelines for the obstetrician-gynecologist. Am J Obstet Gynecol. 1988;159:490–9.CrossRefPubMed
69.
Zerner J, Doil KL, Drewry J, Leeber DA. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26:99–102.PubMed
70.
Yadav BK, Gupta RK, Gyawali P, Shrestha R, Poudel B, Sigdel M, et al. Effects of long-term use of depo-medroxyprogesterone acetate on lipid metabolism in Nepalese women. Korean J Lab Med. 2011;31:95–7.CrossRefPubMedPubMedCentral
Metadata
Title
Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation
Authors
Anjli Maroo
Johnny Chahine
Publication date
01-06-2018
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 3/2018
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-018-0392-x

Other articles of this Issue 3/2018

Current Heart Failure Reports 3/2018 Go to the issue

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Management of Sleep Disordered Breathing in Patients with Heart Failure

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Novel Insights and Treatment Strategies for Right Heart Failure

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Nutritional Interventions in Heart Failure: Challenges and Opportunities

Management of Heart Failure (T. Meyer, Section Editor)

Essential Elements of Early Post Discharge Care of Patients with Heart Failure

Management of Heart Failure (T. Meyer, Section Editor)

Has the Time Come to Be More Aggressive With Bariatric Surgery in Obese Patients With Chronic Systolic Heart Failure?

Clinical Trials (J. Butler, Section Editor)

Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits